Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-06-03

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Levothyroxine Sodium from Lupin Pharmaceuticals, Inc. This action updates the product's labeling under the ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)